Duration of immune protection of SARS-CoV-2 natural infection against reinfection.
التاريخ
2022-09-30المؤلف
Chemaitelly, HiamNagelkerke, Nico
Ayoub, Houssein H
Coyle, Peter
Tang, Patrick
Yassine, Hadi M
Al-Khatib, Hebah A
Smatti, Maria K
Hasan, Mohammad R
Al-Kanaani, Zaina
Al-Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar Hassan
Latif, Ali Nizar
Shaik, Riyazuddin Mohammad
Abdul-Rahim, Hanan F
Nasrallah, Gheyath K
Al-Kuwari, Mohamed Ghaith
Butt, Adeel A
Al-Romaihi, Hamad Eid
Al-Thani, Mohamed H
Al-Khal, Abdullatif
Bertollini, Roberto
Abu-Raddad, Laith J
...show more authors ...show less authors
البيانات الوصفية
عرض كامل للتسجيلةالملخص
The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect of viral immune evasion on duration of protection, and protection against severe reinfection, in Qatar, between February 28, 2020 and June 5, 2022. Three national, matched, retrospective cohort studies were conducted to compare incidence of SARS-CoV-2 infection and COVID-19 severity among unvaccinated persons with a documented SARS-CoV-2 primary infection, to incidence among those infection-naïve and unvaccinated. Associations were estimated using Cox proportional-hazard regression models. Effectiveness of pre-Omicron primary infection against pre-Omicron reinfection was 85.5% (95% CI: 84.8-86.2%). Effectiveness peaked at 90.5% (95% CI: 88.4-92.3%) in the 7th month after the primary infection, but waned to ~ 70% by the 16th month. Extrapolating this waning trend using a Gompertz curve suggested an effectiveness of 50% in the 22nd month and < 10% by the 32nd month. Effectiveness of pre-Omicron primary infection against Omicron reinfection was 38.1% (95% CI: 36.3-39.8%) and declined with time since primary infection. A Gompertz curve suggested an effectiveness of < 10% by the 15th month. Effectiveness of primary infection against severe, critical, or fatal COVID-19 reinfection was 97.3% (95% CI: 94.9-98.6%), irrespective of the variant of primary infection or reinfection, and with no evidence for waning. Similar results were found in sub-group analyses for those ≥50 years of age. Protection of natural infection against reinfection wanes and may diminish within a few years. Viral immune evasion accelerates this waning. Protection against severe reinfection remains very strong, with no evidence for waning, irrespective of variant, for over 14 months after primary infection.
المجموعات
- الأبحاث [709 items ]
- العلوم الحيوية الطبية [692 items ]
- أبحاث فيروس كورونا المستجد (كوفيد-19) [799 items ]
- الرياضيات والإحصاء والفيزياء [722 items ]
- الصحة العامة [401 items ]